Employers, brokers and TPAs need to calibrate their expectations for how Humira biosimilars will impact the cost of prescription drugs for groups and members.
DebugScreen: mobile
{
"author": {
"name": "Brian Shonat",
"webUrl": "/author/profile/brian-shonat/",
"description": "",
"imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
"estimate": 1,
"social": [],
"articles": [
{
"uri": "/2023/04/10/humira-biosimilars-are-finally-here-what-brokers-and-tpas-need-to-know/",
"title": "Humira biosimilars are finally here: What brokers and TPAs need to know",
"byline": "Beckie Fenrick and Brian Shonat",
"kicker": "Market Insights",
"prettyDate": "April 10, 2023",
"timeToRead": "5 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2022/04/Medical-Pills-Article-202204131136.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/beckie-fenrick/",
"name": "Beckie Fenrick"
},
{
"webUrl": "/author/profile/brian-shonat/",
"name": "Brian Shonat"
}
],
"kickerNode": [
{
"uri": "/market-insights/",
"sectionName": "Market Insights"
}
],
"summary": "Employers, brokers and TPAs need to calibrate their expectations for how Humira biosimilars will impact the cost of prescription drugs for groups and members.",
"body": null
}
]
}
}